ライフサイエンスコーパス: antibody to

1 grouped as either HPV seronegative or having antibodies to 1-2 HPV types or to >=3 HPV types.

2 Seasonal IIV could not induce seroprotective antibodies to 2010.1 cluster A(H3N2)v viruses in young c

3 fic Luminex-based assay for immunoglobulin G antibodies to 4 Ebola virus species.

4 Antibodies to 4/18 non-HLA antigens synergize with HLA d

5 he Janus emulsions is assembled by attaching antibodies to a functional surfactant polymer with a tet

6 egimen also increased vaginal and rectal IgA antibodies to a greater extent.

7 le of the microbiota in eliciting protective antibodies to a specific neonatal pathogen represents an

8 ed the levels of heterologous cross-reactive antibodies to A(H3N2)v cluster 2010.1 viruses induced fr

9 iruses in young children, but induced higher antibodies to A(H3N2)v viruses in cluster 2010.1 than th

10 e quantified the binding of the M2 anti-FLAG antibody to a library of 1.3 x 10(4) variant FLAG peptid

11 potential solution to overcome pre-existing antibodies to AAV-based gene therapy.

12 We also saw some expected antibodies to ABO(H) blood group and alpha-Gal-type anti

13 Preclinical studies targeting cells with an antibody to "activated" matriptase conjugated to a poten

14 Neutralizing antibodies to adeno-associated virus (AAV) vectors are h

15 sitive (99%) and specific (93%) detection of antibodies to all FMDV strains used in this study.

16 All vaccines elicited neutralizing antibodies to all H3 vaccine antigens, but the rHA vacci

17 Antibodies to all PfEMP1 types declined at similar rates

18 of 14 infants tested developed neutralizing antibodies to all three Sabin types and also exhibited h

19 At 12 months, children had acquired antibody to all types of CIDR domains, mostly in childre

20 tests or the presence of serum-specific IgE antibodies to allergens.

21 erized by the presence of serum specific IgE antibodies to alpha-gal and delayed type I allergic reac

22 (hi) CD4(+) T cells, but not treatment with antibody to alpha(4)beta(7) , correlated with levels of

23 ession of alpha5 subunit, and a neutralizing antibody to alpha5 subunit reduced adhesion to FN and me

24 ind to the Fc region of target-bound primary antibodies to amplify signals of low-abundant target mol

25 Antibody to antigenic determinant binding was associated

26 ombinant antigens and for IgG and opsonising antibodies to antigens found on infected erythrocytes (I

27 P = .0017), and (v) concomitant presence of antibodies to any of 6 nongenital HPV types (chi2 = 40.1

28 in the affinity maturation of an inhibitory antibody to Arginase 2 (ARG2).

29 ructed a diverse library of >3000 monoclonal antibodies to assess the roles of extracellular loops (E

30 ns regarding numerous studies that used this antibody to assess the distribution and function of Fcep

31 We addressed the overall contribution of antibodies to atherosclerosis plaque formation, composit

32 red test to detect intrathecal production of antibodies to B. burgdorferi is the antibody index assay

33 based assay for the detection of IgM and IgG antibodies to B. burgdorferi The BioPlex 2200 Lyme Total

34 ed by maintenance therapy with belimumab, an antibody to B-cell activating factor.

35 The neutralizing antibodies to benralizumab may have resulted in the recu

36 a, which was possibly caused by neutralizing antibodies to benralizumab.

37 Despite the ability of bi-TPB-PPB antibodies to bind to Fcgamma receptor IIIa and HER2 onc

38 Polyreactivity is the ability of a single antibody to bind to multiple molecularly distinct antige

39 When we used antibodies to block NeSt1 in mice and then allowed Zika

40 novel assay that quantifies the capacity of antibodies to block receptor-ligand interactions (i.e. a

41 The capacity of nonneutralizing V2 antibodies to block this activity reveals a previously u

42 structures in AD-5 that could be targeted by antibodies to block this early step in HCMV infection.IM

43 d injected transgenic mice with anti-ChemR23 antibody to block ChemR23.

44 Generating sufficient antibody to block infection is a key challenge for vacci

45 ru p 3 and rMal d 3 were performed and sIgG4 antibodies to both components quantified.

46 course is consistent with a contribution of antibodies to both viral clearance and progression to se

47 ced human elicited potent cross-neutralizing antibodies to both ZIKV and DENV.

48 This ability of a biparatopic antibody to both crosslink CD73 dimers and fix them in a

49 Antibodies to BPI and bacterial antigens were measured i

50 c nature of this autoreactivity by examining antibodies to BPI in bacteremia patients.

51 Antibodies to C. rectus resulted in the strongest associ

52 was collected from each child and tested for antibodies to C. trachomatis.

53 the safety and efficacy of galcanezumab, an antibody to calcitonin gene-related peptide, in patients

54 Galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a pr

55 Antibodies to Campylobacter rectus, Veillonella parvula,

56 The array contained 40 antibodies to capture sEVs, which were then visualized w

57 ly unique ACAR, which included unanticipated antibodies to carbohydrate antigens not well studied, su

58 treatment with a FcR non-binding monoclonal antibody to CD3 in people at high risk for disease.

59 traversing the barrier and delivering active antibody to cells within the brain.

60 We show that Hawaiian turtles mount antibodies to ChHV5 mainly in response to tumors, which

61 f T-cell memory or if it affects preexisting antibodies to childhood vaccinations or infections.

62 A serologic test for antibodies to chlamydia may be a useful tool for trachom

63 lected on filter paper and dried to test for antibodies to Chlamydia trachomatis pgp3 using the Lumin

64 Antibodies to CIDRalpha1 domains were more frequent in c

65 re more frequent in cord blood compared with antibodies to CIDRalpha2-6 domains.

66 the MODIFY trials.High titers of endogenous antibodies to Clostridioides difficile toxin B, but not

67 Limbic encephalitis associated with antibodies to components of the voltage-gated potassium

68 cell killing of cancer-targeting anti-glycan antibodies to create superior clinical candidates for ca

69 conjugated 211At to an anti-CD38 monoclonal antibody to create an 211At-CD38 therapy.

70 art of the evaluation, tested his plasma for antibodies to cytokines.

71 n glioma treatment with checkpoint inhibitor antibodies to cytotoxic T-lymphocyte-associated antigen

72 stration of serotype-specific IgG monoclonal antibodies to dams demonstrated conclusively that antica

73 highly specific targeting capabilities of an antibody to deliver a cytotoxic payload to specific cell

74 on, mice were treated with IgG or anti-F4/80 antibodies to deplete macrophages during preneoplastic g

75 e mice with either IgG control or anti-F4/80 antibodies to deplete macrophages.

76 -induced reactivation of LTBI, we used CD4R1 antibody to deplete CD4+ T cells in animals with LTBI wi

77 iderations for the assessment of the role of antibodies to derive a serocorrelate of risk reduction i

78 enzymatic digestion, stained with panels of antibodies to detect and quantify cancer cells, along wi

79 -human leukocyte antigen-DR isotope (HLA-DR) antibodies to detect antigen-presenting immune cells.

80 udy of nivolumab, a PD-1 blocking monoclonal antibody, to determine its safety, pharmacokinetics, and

81 ration (FMMS), employing magnetic anti-Tom22 antibodies, to develop a novel strategy for isolation of

82 Antibodies to different PfEMP1 types develop gradually a

83 The ability of a single-domain antibody to discriminate between the most conserved MMP

84 nya (1993-2016) for binding and neutralizing antibodies to distinguish ZIKV and dengue virus (DENV) r

85 Class-switched antibodies to double-stranded DNA (dsDNA) are prevalent

86 s in glomeruli was examined by staining with antibodies to dsDNA, histones H1 and H4, and TATA-bindin

87 specimens from uninfected subjects displayed antibodies to either antigen.

88 We used cell-specific monoclonal antibodies to eliminate neutrophils, monocytes, or both.

89 ssive tumor microenvironment with monoclonal antibodies to enhance NK cell activation and NK cell-med

90 ng Fc engineering of maternally administered antibody to enhance only FcRn binding as a means to impr

91 e and direct functionalization with suitable antibodies to ensure the disease-specific detection of p

92 t hemagglutination test for the detection of antibodies to Entamoeba histolytica (Eh) was positive.

93 Antibodies to EPCR-binding domains increased from presen

94 aged with PKM2-null T cell EVs and anti-CD19 antibody to exert B-cell targeting and inhibit IgG produ

95 Antibodies to FcRn, now in clinical trials in warm autoi

96 s with fractionated radiation and a blocking antibody to FGF2 prolongs tumour growth delay, increases

97 ed and specific and high-affinity monoclonal antibodies to fluopyram were raised for the first time.

98 Linking two half antibodies to form the knob-into-hole bispecific antibod

99 The neutralizing activity of antibodies to gD and gH antibodies was also increased in

100 cific positions of an anti-EGFR single chain antibody to generate an emission wavelength-dependent im

101 Levels of HBGA antibodies to GI.1 but not GII.4c were higher after the

102 Antibodies to glutamic acid decarboxylase (GAD) have bee

103 rs to set up various strategies to conjugate antibodies to gold nanoparticles.

104 Antibodies to golimumab were detected in 30 participants

105 produced broadly cross-reactive neutralizing antibodies to H2 influenza viruses.

106 f human antibodies to NA lags behind that of antibodies to HA.

107 ly than pregnant women without T. gondii IgA antibodies to have had a recent infection with T. gondii

108 Screening tests for antibodies to HCV may generate up to 32% false positivit

109 Prevalence of antibodies to hepatitis A virus (anti-HAV) and hepatitis

110 ntibodies to hepatitis B surface antigen and antibodies to hepatitis B core antigen (anti-HBc) in HBs

111 s measured, including hepatitis B e antigen, antibodies to hepatitis B e antigen, antibodies to hepat

112 e antigen (HBsAg)-positive participants, and antibodies to hepatitis B surface antigen and antibodies

113 ntigen, antibodies to hepatitis B e antigen, antibodies to hepatitis D, hepatitis B virus (HBV) DNA f

114 Among adult HBsAg carriers, 42% had antibodies to hepatitis delta virus (anti-HDV).

115 r transplantation from an donor positive for antibody to hepatitis B core antigen (anti-HBc).

116 gen (HBsAg; prevalence of HBV infection) and antibody to hepatitis B core antigen (anti-HBc; prevalen

117 Levels of antibody to hepatitis B surface antigen (HBsAg) (anti-HB

118 i-HBc) total immunoglobulin (Ig) or IgG, and antibody to hepatitis B surface antigen-but anticancer t

119 background free-electronic detection of IgG antibodies to HIV and Ebola viruses.

120 human immunodeficiency virus (HIV)-specific antibody to HIV-infected persons leads to the developmen

121 Patients with antibodies to HLA wait longer for transplant and are at

122 MS patients make antibodies to hnRNP A1, which have been shown to lead to

123 onses were detected in all animals, although antibodies to HSV-2 were detected in only 30% of the ani

124 e immunogenic in natural infections and that antibodies to HYP1 are associated with clinical protecti

125 ation Sequencing (eCLIP-seq) using anti-AGO2 antibody to identify potential microRNA (miRNA) binding

126 owledge of specific targets and functions of antibodies to IE surface antigens that protect against s

127 Antibodies to IE surface antigens were examined in a cas

128 mmercial OS tumors in mice with radiolabeled antibody to IGF2R and to investigate IGF2R expression on

129 utions of CD4(+) T cells, CD8(+) T cells and antibodies to immunity and memory recall.

130 radiation in combination with Ang2-blocking antibodies to improve the overall outcome of cancer trea

131 CD8 T cells, and with anticancer monoclonal antibodies to increase ADCC and antitumor efficacy, have

132 hese findings highlight the capacity for IgG antibodies to induce protective adaptive immunity to vir

133 ith a single dose of IFN-I receptor-blocking antibody to induce a short-term blockade of the IFN-I pa

134 cental transfer of NTS LPS-specific maternal antibodies to infants was highly efficient.

135 mline gene used by many broadly neutralizing antibodies to influenza A virus, Sangesland et al. show

136 rmin treatment and anti-IL-6 (interleukin-6) antibodies to inhibit the IL-6 pathway.

137 The efficiency of M204-scFv antibodies to inhibit the seeding by brain tissue extrac

138 To examine the ability of each antibody to inhibit phagocytosis of platelets, the antib

139 cell types are bound by these anti-leukocyte antibodies to initiate an immunologic cascade resulting

140 this increase was blocked by a neutralizing antibody to integrin alpha(V)beta(5).

141 sits flat against the membrane to allow the antibody to interact with SSEA-4 on cancer cells.

142 Dupilumab is a fully human antibody to interleukin-4 receptor alpha that improves t

143 ti-EpCAM (epithelial cell adhesion molecule) antibodies to isolate CTCs from human blood samples.

144 2), and more than 10 times that number carry antibodies to it.

145 E8 and PE9), conjugated with fluorophore and antibody, to make stable DNA origamis with imaging and c

146 We evaluated persistence of antibodies to measles vaccination at 4.5 years of age in

147 e describe a new assay that uses GP-specific antibodies to measure GP thermostability under a variety

148 ) technology uses panels of high-specificity antibodies to measure proteins and protein post-translat

149 l inhibition, including when using different antibodies to measure the same target antigens.

150 y diminished the binding of vaccine-elicited antibodies to membrane-anchored gp160.

151 Fluorescent antibody to membrane antigen (FAMA) assays and glycoprot

152 that naturally-acquired and vaccine-induced antibodies to merozoite surface protein 2 (MSP2) are ass

153 RB1 is the parental antibody to MK-1654 which is currently in clinical devel

154 ial use and limitations of using therapeutic antibodies to modulate GPCR signaling.

155 This study demonstrates that the MAR-1 antibody to mouse FcepsilonRI unexpectedly binds to two

156 Presence of antibodies to multiple anogenital HPV types at baseline

157 Receptor crosslinking requires binding of antibodies to multiple epitopes on the allergen.

158 would need to elicit broadly cross-reactive antibodies to multiple H2 influenza viruses.

159 egative for AQP4-IgG, pathogenetic serum IgG antibodies to myelin oligodendrocyte glycoprotein, an an

160 This study demonstrates that human antibodies to N1 NA with exceptional cross-reactivity ca

161 Analysis of human antibodies to NA lags behind that of antibodies to HA.

162 This suggests that antibodies to NA may be a useful therapy and that the ef

163 from PCD patients as well as CDR2 and CDR2L antibodies to neuronal tissue, cancer cell lines, and ce

164 olecularly cloned SIVmac239 is difficult for antibodies to neutralize, and a variety of vaccine appro

165 isease mechanism caused by immunoglobulin G4 antibodies to nodal or paranodal proteins, and could req

166 These results suggest that antibodies to non-HLA are associated with DSA-positive A

167 bottleneck may improve our ability to elicit antibodies to non-immunodominant epitopes by vaccination

168 ative antigen for vaccine development, since antibodies to NS1 do not bind to the virion, thereby eli

169 Using the simultaneous presence of antibodies to nucleoproteins and glycoproteins to define

170 gG in juvenile mice and vertical transfer of antibodies to offspring following maternal vaccination.

171 Antibodies to oral pathogens can be considered an indire

172 Florida, we rejected the cross-reactivity of antibodies to other herpesviruses, differences in viral

173 a novel approach to rule out cross-reactive antibodies to other seasonal influenza viruses to determ

174 ted by nonspecific binding of its respective antibody to other nontarget cellular regions.

175 site-specific PTM quantitation of monoclonal antibodies to overcome this limitation.

176 tvaccination was tested for immunoglobulin G antibodies to P. falciparum circumsporozoite protein (Pf

177 Ustekinumab, an antibody to p40, blocks cytokines IL-12 and IL-23, and i

178 tion therapy to provide protective levels of antibodies to patients with primary immune deficiency di

179 ing administration of therapeutic monoclonal antibody to patients is a growing problem that is attrac

180 We have developed a specific antibody to Pcdh-gammaC4 to reveal the expression of thi

181 with T cell-directed immunotherapy, such as antibodies to PD-1 or PD-L1, to enhance tumor killing.

182 either as monotherapy or in combination with antibody to PD-1 or to its ligand PD-L1.

183 e combined to verify any association between antibodies to periodontal microbiota and BP.

184 one-week post-vaccination was tested for IgG antibodies to Pf circumsporozoite protein (PfCSP) using

185 d 4 of 21 (19.0%) placebo controls developed antibodies to PfCSP (P < .001).

186 and 4/21 (19.0%) placebo controls developed antibodies to PfCSP, p<0.001.

187 sistant to PM over successive pregnancies as antibodies to placental IE are acquired.

188 We collected cord blood, measured antibodies to Plasmodium falciparum Schizont Egress Anti

189 uction of FXa activity by ICs containing IgG antibodies to platelet factor 4 (PF4) involved in hepari

190 Treatment with monoclonal or polyclonal antibodies to PNAG (anti-PNAG) or vaccination against PN

191 (DBS) specimens were tested for neutralizing antibodies to poliovirus types 1, 2, and 3 in 580 younge

192 Antibodies to polyomaviruses were evaluated as a control

193 ates that the liver is an important site for antibodies to prevent malaria.

194 Immunotherapy with antibodies to programmed death 1 (PD-1) produces lower r

195 However, the ability of antibodies to protect against CMV infection is not well

196 The immunized dams transfer maternal antibodies to pups, which protect neonates against ZIKV

197 LYVE-1 followed by Cy3-conjugated secondary antibody to quantify corneal blood and lymphatic vessels

198 of CD274, which combined with the anti-PD-L1 antibody to reactivate T cells function for tumor attack

199 stable while maintaining the ability of the antibody to recognize and bind its corresponding antigen

200 While antibodies to recombinant antigens declined between enro

201 APTB was associated with higher levels of antibodies to respiratory syncytial virus and measles vi

202 e, patterns of, and factors associated with, antibodies to RVF virus (RVFV) in livestock in an area h

203 drug, consisting of released-active form of antibodies to S-100 protein, tumor necrosis factor-alpha

204 , and (c) there was cross-reactivity between antibodies to SARS-CoV-1 and SARS-CoV-2, but only antibo

205 Accurate assays for the detection of antibodies to SARS-CoV-2 (severe acute respiratory syndr

206 application of serological assays to detect antibodies to SARS-CoV-2 are essential to determining se

207 Antibodies to SARS-CoV-2 demonstrate infection when meas

208 y investigates the prevalence of IgG and IgM antibodies to SARS-CoV-2 in Los Angeles County, Californ

209 Antibodies to SARS-CoV-2 predicted the odds of developin

210 PCR) test result and who were tested for IgG antibodies to SARS-CoV-2 spike protein at least 2 weeks

211 Antibodies to SARS-CoV-2 spike S1 protein and its recept

212 a high-throughput multiplex assay to detect antibodies to SARS-CoV-2 to assess immunity to the virus

213 eflectometry (AIR) platform for detection of antibodies to SARS-CoV-2, SARS-CoV-1, MERS, three circul

214 Most patients with COVID-19 lack antibody to SARS-CoV-2 in the first 10 days of illness w

215 Stratifying by gravidity, antibody to schizont extract decreased more in multigrav

216 ive of survival.CONCLUSIONThe measurement of antibodies to selected epitopes of SARS-CoV-2 antigens c

217 ion and thus represents the first monoclonal antibody to selectively inhibit distinct PTH1R signaling

218 The relationship between the presence of antibodies to severe acute respiratory syndrome coronavi

219 Accurate serologic tests to detect host antibodies to severe acute respiratory syndrome-related

220 Immunoassays were ranked into 3 tiers, with antibodies to Shigella lipopolysaccharide (LPS) being th

221 This binding mode limits the IGHV3-53 antibodies to short complementarity-determining region H

222 MAPq utilizes lanthanide-conjugated antibodies to simultaneously quantify up to 35 proteins

223 ter repeated infections as children age, and antibodies to specific CIDR types may confer protection.

224 on the principle that binding of monoclonal antibodies to specific epitopes of T. b.

225 0% sensitivity and 100% specificity, whereas antibodies to spike protein were detected with 91% sensi

226 Many people had pre-existing antibodies to SpyTag:SpyCatcher but less to the 003 vari

227 ften require thermostabilizing mutations and antibodies to stabilize a specific conformation, leading

228 nse was observed in relation to specific IgE antibodies to Staphylococcus aureus enterotoxins.

229 ic window determined by competing effects of antibodies to stimulate receptors and induce their downr

230 Here we detect antibodies to Streptococcus pyogenes Cas9 (SpCas9) in at

231 The prevalence of antibodies to Strongyloides stercoralis was measured in

232 In this work, we have used Nd-labeled antibodies to tag the TfR1 present on the cell surface o

233 stem, we demonstrate that TRIM21 uses anti-N antibodies to target N for cytosolic degradation and gen

234 th a significant decrease in the capacity of antibodies to target the viral glycoprotein, hemagglutin

235 gely increased the accumulation of detection antibody to target molecules, which dramatically enhance

236 oven therapeutic antibodies as well as novel antibodies to targets that have been previously inaccess

237 s by cross-linking pMHC or using multivalent antibodies to TCR.

238 ies cross-reactive, and brain-selective VNAR antibody to TfR1 that rapidly crosses the BBB and exhibi

239 Injection of inhibitory antibodies to the alpha subunit of the Gs heterodimeric

240 Antibodies to the blood stages of malaria parasites enha

241 Selected antibodies to the CD4-binding site bolster envelope trim

242 Binding of antibodies to the CoRBS permits another family of nnAbs,

243 C-SPDP) to enhance the immobalization of the antibodies to the detection electrodes.

244 We further showed that levels of antibodies to the domain of PfRh2 protein were similar t

245 Serum antibodies to the E6, E7, E1, E2, and L1 proteins of 7 h

246 ection, and attention has turned to inducing antibodies to the envelope.

247 We observed a major synchronous expansion of antibodies to the HCoV-OC43 and HCoV-HKU1 spike S2.

248 cines to offer optimal protection.IMPORTANCE Antibodies to the influenza virus NA can provide protect

249 pylobacter jejuni infection that has induced antibodies to the lipo-oligosaccharide (LOS) that cross-

250 and biodistribution of SARS-CoV-2 targeting antibodies to the lungs.

251 The COBRA HA vaccines elicited neutralizing antibodies to the majority of viruses in our H2 HA panel

252 Here, accessibility of antibodies to the native Env MPER on single virions has

253 active, potentially even cross-neutralizing, antibodies to the new species in humans is unclear.

254 Using newly developed phosphosite-specific antibodies to the NOP receptor, we found that agonist-in

255 Using specific antibodies to the NSPs along with our labeled inhibitors

256 Quantitative measurements of plasma or serum antibodies to the nucleocapsid and spike proteins were a

257 ic high-resolution CT findings, specific IgG antibodies to the offending antigen, bronchoalveolar lav

258 ) DISC (DISCII) vaccine induces neutralizing antibodies to the PC and other glycoproteins and a cell-

259 gress Antigen-1 (PfSEA-1), and related these antibodies to the risk of severe malaria in the first ye

260 ubstrates, for the simultaneous detection of antibodies to the S1 subunit of the spike protein and to

261 Achieving high levels of neutralizing antibodies to the spike protein of SARS-CoV-2 in a safe

262 d the development of resistance against four antibodies to the spike protein that potently neutralize

263 ) assays, we characterized IgG, IgM, and IgA antibodies to the spike receptor binding domain (RBD), S

264 ntigen conjugates trigger the recruitment of antibodies to the surface of cancer cells and induce cyt

265 thod to identify high affinity single domain antibodies to the transferrin receptor 1 (TfR1) with eff

266 compared with the aPV that primarily induced antibodies to the vaccine antigens.

267 nt infection with EBOV and that neutralising antibodies to the viral surface glycoprotein (GP) are po

268 ted individuals develop broadly neutralizing antibodies to the virus (bNAbs).

269 In this work, we produced neutralizing antibodies to the virus and mapped the epitopes they rec

270 ells, and the addition of the LAG-3-blocking antibody to the adoptive transfer protocol improved the

271 Reducing adhesion to FN by an inhibitory antibody to the alpha5 subunit effectively reduces the p

272 cessful SIV/HIV-1 protective vaccines induce antibody to the envelope and neutralize the virus or med

273 eproduced when wild-type FXII is bound by an antibody to the FXII heavy chain (HC; 15H8).

274 al antibody mAb3104 and a newly made peptide antibody to the gI extracellular domain (ECD) (amino aci

275 ous central administration of a neutralizing antibody to the IFN-alpha/beta receptor (IFNAR) for 3 d,

276 Antibody to the nucleocapsid protein of SARS-CoV-2 is mo

277 by not expressing cell surface E2 or binding antibody to the plasma membrane.

278 nterface relied on direct conjugation of the antibody to the polymer membrane and the second one reso

279 ma had received off-label therapeutic use of antibody to the programmed death-1 protein (anti-PD-1) a

280 eatment of SINV-Broccoli-infected cells with antibody to the SINV E2 glycoprotein had cell type-speci

281 ental transfer of vaccine-induced protective antibodies to their newborn infants.

282 undamental information relating sequences of antibodies to their unique properties as inhibitors.

283 Human antibodies to this protein also exhibit erythrocyte bind

284 ride facilitated the pursuit of a monoclonal antibody to this synthetic hapten.

285 Despite low plasma titres, antibodies to three distinct epitopes on the RBD neutral

286 Binding antibodies and neutralizing antibodies to tier 1 viral isolates were detected in the

287 antation, the presence of naturally-existing antibodies to TKO pig cells in OWMs complicates the tran

288 tation because many humans have no preformed antibody to TKO pig cells.

289 cause many humans have minimal or no natural antibody to TKO pig cells.

290 different ages using custom-made polyclonal antibodies to TMC1 for light and transmission electron m

291 the inflamed brain is >10-fold greater than antibodies to transferrin receptor-1 and intercellular a

292 qualitative test for the detection of human antibodies to Treponema pallidum." The Syphilis Health C

293 ed by the bivalent binding of a specific IgG antibody to two antigen-conjugated DNA templating strand

294 ultiplexing snRNA-seq, using sample-barcoded antibodies to uniquely label nuclei from distinct sample

295 Detection of antibodies to upper respiratory pathogens is critical to

296 n experimental studies, we used a monoclonal antibody to urokinase plasminogen activator receptor (uP

297 Accordingly, we generated 21 novel antibodies to various mitochondrial proteins and used th

298 found that uptake of intravenously injected antibody to vascular cell adhesion molecule 1 (anti-VCAM

299 eropositive subjects, including high-avidity antibodies to viral antigens, coverage against a panel o

300 f administration of anti-IL11 or anti-IL11RA antibodies to wild-type mice on the HFMCD or WDF, or to